Livermore

STEINMAN LAWRENCE

SEC CIK
0001132679

Latest role at each company

Trades

Every Form 4 that lists STEINMAN LAWRENCE as a reporting owner, including filings made jointly with others. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.

Insider trades
CompanyFiled (ET)Trade dateInsiderTransactionSharesAvg priceValueShares afterHolding changeFiling
KTTAPasithea Therapeutics Corp.Dec 1, 2025Nov 28, 2025STEINMAN LAWRENCEDirectorPPurchaseCommon Stock+133.33K$0.75+$100K199.69K+200.9%SEC
BCABBioAtla, Inc.Dec 19, 2023Dec 19, 2023STEINMAN LAWRENCEDirectorPPurchaseCommon Stock+20K$2.05+$41K38.46K+108.3%SEC
KTTAPasithea Therapeutics Corp.Jun 6, 20239:00 PM ETJun 2, 2023STEINMAN LAWRENCEDirectorPPurchaseCommon Stock+30K$0.431+$12.93K1.33M+2.3%SEC
FRMMFORUM MARKETS IncJun 2, 2023Jun 1, 2023STEINMAN LAWRENCEDirectorPPurchaseCommon Stock+18K$1.23+$22.14K48.13K+59.7%SEC
FRMMFORUM MARKETS IncDec 10, 2021Dec 9, 2021STEINMAN LAWRENCEDirectorPPurchaseCommon Stock+5K$4.27+$21.35K602.57K+0.8%SEC
BCABBioAtla, Inc.Nov 3, 2021Nov 2, 2021STEINMAN LAWRENCEDirectorSSaleCommon Stock−450$30.00−$13.5K18.46K−2.4%SEC
BCABBioAtla, Inc.Sep 17, 2021Sep 15, 2021STEINMAN LAWRENCEDirectorSSaleCommon Stock−450$36.82−$16.57K18.91K−2.3%SEC
BCABBioAtla, Inc.Aug 18, 2021Aug 16, 2021STEINMAN LAWRENCEDirectorSSaleCommon Stock−450$40.60−$18.27K19.36K−2.3%SEC
BCABBioAtla, Inc.Jul 19, 2021Jul 15, 2021STEINMAN LAWRENCEDirectorSSaleCommon Stock−450$38.29−$17.23K19.81K−2.2%SEC